Vivior EN

Vivior

Vivior has developed the Vivior Monitor – the first “Fitbit for the eyes”!

210819_Exposé_Vivior_EN

Vivior Investment Exposé

Share your email address with us to receive investment information

Early-bird bonus +1% base-interest bis 22.09!

Quick Facts

Frame 4
Frame 2 (1)
Frame 3
swiss
Investment-Type: Subordinated Loan

Venture Category

Digital Device

Financing Round

Series A

Business Phase
Growth
Investment Offer

Funding Target

€ 2.5 m

Term

31.12.2026

Company Valuation

€ 12.5 m

Investors’ Yield

3.0% base-interest p.a. + full participation in increase of company value

Overview

The Vivior monitor is a lightweight, user-friendly device for objective measurement of visual behavior.

Founded in 2017 out of Zurich, Vivior AG now uses AI activity recognition as well as visual behavioral assessment to objectively and accurately determine the best lenses for patients’ and customers’ specific needs.

Strong starting position

Vivior AG has already invested € 5.9 m and today the company already has an existing customer base of more than 100 B2B customers, including leading companies in the field of ophthalmic optics and ophthalmology.

What's the catch? We are still searching today.

Run by specialists

Founded at that time by 5 experienced specialists, today the team consists of a globally recognized medical advisory board and a team of 9 experienced employees.

Lucrative business model

The business model consists of recurring user fees for the use of the device and data analysis. In this context, the solution is aimed at all end users who need a visual aid. Target groups are:

  • Eye specialists: ophthalmologists, optometrists, opticians
  • Employers
  • Digital health platforms

Financial planning with break-even in 2024

Planned sales are approximately €30 m for 2024. In the long term, Vivior projects an EBIT margin of >25%.

What makes Vivior unique?

Vivior is the only solution that links eye health with objective data on vision behavior, enabling eye care professionals, optometrists and opticians to find the optimal vision solution for better vision, well-being and health.

Key Highlights

Vivior measures actual visual behavior using LIDAR technology

Objective measurement of visual behavior, ergonomics, and lifestyle habits over just a few days to get an accurate picture of patient and client needs - without the bias that comes with traditional approaches.

Multiple application fields

Vivior addresses its product to a sufficiently large market: the market for visual aids in general is €165 billion, the premium segment of which is $17 billion, and the market for ophthalmic diagnostic devices is still $1.7 billion.

Vision correction

Fully personalized vision correction services based on the real needs of each patient’s daily life.

Prevention

Vivior Myopia Analysis, which helps parents better understand their children’s myopia risk and manage long-term vision and eye health.

Performance

Personalized applications to improve visual performance for better results in recreational activities leading to a better lifestyle and overall health.

Digital office health

Vivior workplace analysis to reduce the physical and psychological effects of computer vision syndrome, including neck and shoulder pain, headaches and eye strain.

Great potential for the future

Through cross-sector partnerships and the provision of solutions for "Digital Health in the Office", Vivior creates a promising environment for versatile opportunities for success. Specific plans for the technology, telemedicine, insurance, ECPs (eye-care professionals) and large enterprise sectors in general promise high revenue growth.

Management Team

Entrepreneurs with excellent track records, accompanied by a scientific advisory board of leading European researchers.

Prof. Michael Mrochen, Ph.D.
Chairman of the Board of Directors
  • Serial entrepreneur with previous exits (Avedro; IROC Innocross, Clear Sight Innovations; Alcon)
  • Globally recognized scientist
  • Created hundreds of millions of $ in shareholder value through innovative products
Pavel Zakharov, Ph.D.
Head of the Technology Department
  • PhD in biomedical optics and laser biophysics
  • Technological expert in several startups focusing on innovative medical sensor technology and wearable monitoring devices
Mario Stark, MA
Executive Director
  • Experience as CEO of several startups
  • Executive in large medical device companies
  • Board member of several startups in the medical device, wearable sensor and digital health industries

 

Paul J. Soye, Ph.D., MBA
US Operations & Member of the Board of Directors
  • Former global head of cataract surgery research and development at Alcon, based in Fort Worth, TX, USA
  • Founder of Hibernian Consulting LLC

Board of Directors

Guido Wietlisbach
Board of Directors
Oscar Groet
Board of Directors
Richard Fritschi
Board of Directors

Advisory Board

In addition to the Board of Directors, Vivior has a Medical Advisory Board, a Scientific Advisory Board and a Health Advisory Board consisting of internationally recognized experts.

Downloads

Edit

Vivior Investment Exposé

Teilen Sie uns ihre Mail Adresse mit, um Investment Informationen zu erhalten

Vivior Investment Exposé

Share your email address with us to receive investment information

Contact

Vivior AG Contact & Legal Notice

Vivior AG

Technoparkstrasse 1, 8005 Zürich, Schweiz

Company-ID: CHE-292.149.349
Responsible commercial register: Handelsregisteramt des Kantons Zürich
Founding year: 2017
Managing Directors: Mario Stark, Michael Mrochen

Notice under Section 12 (2) & (3) of the German Investment Act (Vermögensanlagengesetz)

The acquisition of this investment is associated with considerable risks and may lead to the complete loss of the invested assets. The promised return is not guaranteed and may also be lower. aescuvest GmbH does not guarantee that reported interest will actually be achieved.

More information can be found under risk information.

vivior_logo_text

Download Vivior Investment information now!

Vivior Investment Exposé

Share your email address with us to receive investment information